FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| APG777 | Atopic Dermatitis | PHASE2 | ACTIVE_NOT_RECRUITING |
| APG990 | Atopic Dermatitis | PHASE1 | ACTIVE_NOT_RECRUITING |
| Dupilumab | Atopic Dermatitis | PHASE1 | ACTIVE_NOT_RECRUITING |
APGE holds $451.8M in cash and burns about $59.1M/quarter from operations, giving an estimated runway of 22.9 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for APGE free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-06-12 | HENDERSON MICHAEL THOMAS |
Sale | $91.2M |
| 2026-06-12 | HENDERSON MICHAEL THOMAS |
Sale | $91.2M |
| 2026-06-12 | HENDERSON MICHAEL THOMAS |
Sale | $92.6M |
| 2026-06-12 | HENDERSON MICHAEL THOMAS |
Sale | $93.6M |
| 2026-06-12 | HENDERSON MICHAEL THOMAS |
Sale | $94.6M |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for APGE and 2 more tickers of your choice.
Create Free Account →